{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-048942","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2026-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.482380+00:00","generated_at":"2026-05-16T03:06:03.318039+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Xilio Therapeutics prices $40M pre-funded warrant offering; lead investor Coastlands Capital","bullets":["Pre-funded warrants to purchase 74,780,300 common shares at $0.5349/warrant; exercise price $0.0001/share.","Gross proceeds ~$40M; net proceeds ~$37.1M after underwriting discounts and offering expenses.","Offering led by Coastlands Capital with participation from Gilead, OrbiMed, Perceptive Advisors.","Expected closing date February 13, 2026; net proceeds for product development and general corporate purposes.","Pre-funded warrants immediately exercisable; beneficial ownership capped at 4.99% (holder can elect up to 19.99%)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-048942","json":"https://secwatch.observer/filing/0001193125-26-048942.json","markdown":"https://secwatch.observer/filing/0001193125-26-048942.md","text":"https://secwatch.observer/filing/0001193125-26-048942.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526048942/0001193125-26-048942-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526048942/d85184d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:06:03.318039+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"302dd3b1599a5dc0a63fc8ed3632f44471eab53f","claim":"Xilio Therapeutics, Inc. entered into Underwriting Agreement with Leerink Partners LLC valued at approximately $37.1 million (effective 2026-02-11).","evidence_excerpt":"On February 11, 2026, Xilio Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, as representative of the underwriter named therein (the “Underwriter”), relating to an underwritten offering (the “Offering”) of pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 74,780,300 shares of common stock (the “Warrant Shares”) at a price to investors of $0.5349 per Pre-Funded Warrant.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526048942/0001193125-26-048942-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Leerink Partners LLC"},{"label":"Value","value":"approximately $37.1 million"},{"label":"Effective","value":"2026-02-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}